METIS Phase 3 Clinical Trial Met Primary Endpoint, Demonstrating a Statistically Significant Extension in Time to Intracranial Progression for Patients with Brain Metastases from Non-Small Cell Lung Cancer
Retrieved on:
Wednesday, March 27, 2024
Neurology, Radiology, Biotechnology, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, EST, Baptist Health, METIS, Baptist Health South Florida, NSCLC, Webcast, Patient, Radiosurgery, Brain, Regulation, SRS, Disclosure, MD, Quality of life, Lung cancer, Congress, Regulation Fair Disclosure, Clinical trial, Cognition, Radiation therapy, Medical imaging
Patients treated with TTFields therapy and supportive care exhibited a median time to intracranial progression of 21.9 months compared to 11.3 months in patients treated with supportive care alone for brain metastasis (n=298; hazard ratio=0.67; P=0.016).
Key Points:
- Patients treated with TTFields therapy and supportive care exhibited a median time to intracranial progression of 21.9 months compared to 11.3 months in patients treated with supportive care alone for brain metastasis (n=298; hazard ratio=0.67; P=0.016).
- Median TTFields therapy treatment duration was 16 weeks and median usage was 67%.
- Consistent with previous studies, TTFields therapy was well-tolerated with sustained quality of life and neurocognitive function.
- Certain secondary endpoints showed positive trends in favor of treatment with TTFields therapy, including time to distant progression and quality of life.